Masayuki Tsujimoto
Overview
Explore the profile of Masayuki Tsujimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamaya N, Hashimoto T, Ikeda S, Brilliant T D, Tsujimoto M, Nakagawa S, et al.
Neuroimage
. 2024 Jun;
297:120709.
PMID: 38936650
Introduction: The extended practice of meditation may reduce the influence of state fatigue by changing neurocognitive processing. However, little is known about the preventive effects of one-session brief focused attention...
2.
Tabuchi Y, Tsujimoto M, Yamamoto K, Shimizu R, Kosaka T, Sakaguchi K, et al.
Biol Pharm Bull
. 2023 Jul;
46(7):964-968.
PMID: 37394646
Trastuzumab is a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) that is indicated for the treatment of HER2-positive breast cancer. The administration of biologics, such as...
3.
Tsujimoto M, Matsuzaki Y, Yamaya N, Kawashima R
eNeuro
. 2023 May;
10(6).
PMID: 37221088
Despite the significant health consequences of anxiety, the neural basis of regulation for personal anxious events is not well understood. We examined brain activity and functional connectivity during cognitive emotion...
4.
Tabuchi Y, Tsujimoto M, Yamamoto K, Kosaka T, Sakaguchi K, Dobuchi N, et al.
Cancer Chemother Pharmacol
. 2022 Nov;
91(1):25-31.
PMID: 36401659
Purpose: Pertuzumab (Per) is a humanized monoclonal antibody used in combination with trastuzumab (Tra) in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. The administration of biologics,...
5.
Tsujimoto M, Saito T, Matsuzaki Y, Kojima R, Kawashima R
Neuroimage
. 2022 Jun;
257:119334.
PMID: 35643265
Appropriate emotion regulation is crucially involved in mental and physical health. The neural basis of negative but not positive emotion regulation has been well investigated. Several strategies should be compared...
6.
Ogawa A, Hira D, Tsujimoto M, Nishiguchi K, Endo M, Ono T, et al.
Ther Drug Monit
. 2021 Aug;
44(3):396-403.
PMID: 34407000
Background: The optimal sampling points and thresholds for initial serum vancomycin (VCM) concentrations have not been determined in hemodialysis (HD) patients. To clarify this, multiple blood tests were performed, and...
7.
Katsube Y, Tsujimoto M, Koide H, Hira D, Ikeda Y, Minegaki T, et al.
Drug Metab Dispos
. 2021 Jan;
49(4):289-297.
PMID: 33446524
Growing evidence suggests that certain glucuronides function as potent inhibitors of CYP2C8. We previously reported the possibility of drug-drug interactions between candesartan cilexetil and paclitaxel. In this study, we evaluated...
8.
Kado Y, Tsujimoto M, Fuchida S, Okano A, Hatsuse M, Murakami S, et al.
Biol Pharm Bull
. 2020 Aug;
43(8):1253-1258.
PMID: 32741946
Long-term combination treatment with lenalidomide and low-dose dexamethasone is important to achieve a curative effect in patients with multiple myeloma (MM). In this study, the plasma concentration of lenalidomide was...
9.
Olaparib Potentiates Anticancer Drug Cytotoxicity 53BP1 in Oesophageal Squamous Cell Carcinoma Cells
Miyamoto K, Minegaki T, Hirano S, Hayashi I, Tsujimoto M, Nishiguchi K
Anticancer Res
. 2020 Feb;
40(2):813-823.
PMID: 32014924
Background/aim: Olaparib was previously shown to synergistically enhance the cytotoxicity of DNA synthesis inhibitors in oesophageal carcinoma (OC) cell lines. However, the mechanisms of this synergy are not fully understood....
10.
Honda S, Tsujimoto M, Minegaki T, Mori T, Muraoka J, Nishiguchi K
J Clin Pharm Ther
. 2019 Nov;
45(2):373-375.
PMID: 31671217
What Is Known And Objective: Oxaliplatin is a platinum drug used for treating digestive cancers that can lead to drug-induced thrombocytopenia (DITP). We report a case of oxaliplatin-induced anaphylaxis and...